Teladoc Health, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:TDOC
Previous Symbol
CUSIPN/A
Phone203-635-2002
Debt
Debt-to-Equity Ratio0.40
Current Ratio8.99
Quick Ratio8.99
Price-To-Earnings
Trailing P/E Ratio-33.05
Forward P/E Ratio-37.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$233.28 million
Price / Sales16.39
Cash FlowN/A
Price / Cash FlowN/A
Book Value$9.80 per share
Price / Book5.57
Profitability
EPS (Most Recent Fiscal Year)($1.65)
Net Income$-106,780,000.00
Net Margins-31.32%
Return on Equity-14.05%
Return on Assets-9.11%
Miscellaneous
Employees1,231
Outstanding Shares70,110,000
Market Cap$3.74 billion
OptionableOptionable
Teladoc Health (NYSE:TDOC) Frequently Asked Questions
What is Teladoc Health's stock symbol?
Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc Health's earnings last quarter?
Teladoc Health Inc (NYSE:TDOC) announced its quarterly earnings results on Thursday, November, 1st. The health services provider reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.02. The health services provider had revenue of $111 million for the quarter, compared to analysts' expectations of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The company's revenue was up 61.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.55) earnings per share. View Teladoc Health's Earnings History.
When is Teladoc Health's next earnings date?
What guidance has Teladoc Health issued on next quarter's earnings?
Teladoc Health updated its fourth quarter earnings guidance on Thursday, November, 1st. The company provided earnings per share (EPS) guidance of ($0.38)-($0.36) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.34). The company issued revenue guidance of $119-$121 million, compared to the consensus revenue estimate of $117.50 million.
What price target have analysts set for TDOC?
17 equities research analysts have issued 1-year price targets for Teladoc Health's shares. Their predictions range from $56.00 to $100.00. On average, they expect Teladoc Health's share price to reach $84.8235 in the next year. This suggests a possible upside of 53.2% from the stock's current price. View Analyst Price Targets for Teladoc Health.
What is the consensus analysts' recommendation for Teladoc Health?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teladoc Health.
What are Wall Street analysts saying about Teladoc Health stock?
Here are some recent quotes from research analysts about Teladoc Health stock:
- 1. Canaccord Genuity analysts commented, "We remain confident in our above-consensus estimate (~22k) for Q2 unit sales, as web traffic trends and used car market strength suggest CVNA continues to generate healthy gains in consumer mindshare. Moreover, third-party data (including transactional inputs from DataWeave) imply unit sales above consensus and our estimates. While Q3 guidance is somewhat of a wildcard (early signals are positive) we continue to like shares at current levels. Reiterate Outperform rating." (8/2/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on TDOC shares and raise our 12-month price target to $52 from $50. On August 1, TDOC reported 2Q18 results. Revenue was above our estimate and FactSet consensus. Adjusted EBITDA was ahead of consensus expectations as well. The company raised its 2018 guidance to reflect the acquisition of Advance Medical, recognizing the TRICARE launch is slightly delayed. Revenue grew 112%, or 39% organically. We continue to believe that TDOC is positioned to benefit from solid telehealth growth, but that the shares’ current valuation already reflects the strong growth potential." (8/1/2018)
Has Teladoc Health been receiving favorable news coverage?
News articles about TDOC stock have been trending very positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Teladoc Health earned a news sentiment score of 3.9 on InfoTrie's scale. They also gave media coverage about the health services provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Teladoc Health's key competitors?
Some companies that are related to Teladoc Health include Ono Pharmaceutical (OPHLF), Laboratory Corp. of America (LH), ABIOMED (ABMD), Merck KGaA (MKGAF), Incyte (INCY), GRIFOLS S A/S (GRFS), Henry Schein (HSIC), Hologic (HOLX), Cooper Companies (COO), WellCare Health Plans (WCG), Quest Diagnostics (DGX), Teleflex (TFX), Universal Health Services (UHS), IPSEN S A/S (IPSEY) and Varian Medical Systems (VAR).
Who are Teladoc Health's key executives?
Teladoc Health's management team includes the folowing people:
- Mr. Jason Nathanial Gorevic, CEO & Director (Age 46)
- Mr. Peter A. McClennen, Pres (Age 49)
- Mr. Mark J. Hirschhorn, Exec. VP, COO & CFO (Age 53)
- Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 43)
- Dr. Lewis Levy M.D., FACP, Chief Medical Officer (Age 59)
When did Teladoc Health IPO?
(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Teladoc Health's major shareholders?
Teladoc Health's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (10.61%), Vanguard Group Inc. (8.38%), Alliancebernstein L.P. (3.47%), Eagle Asset Management Inc. (2.64%), Bamco Inc. NY (2.56%) and Gilder Gagnon Howe & Co. LLC (2.16%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Lp Chp III, Mark Hirschhorn, Michael Goldstein, Michael H King, Peter A Mcclennen, Stephany Verstraete and Trident Capital Fund Vi Lp. View Institutional Ownership Trends for Teladoc Health.
Which institutional investors are selling Teladoc Health stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Capital World Investors, Alliancebernstein L.P., Global Thematic Partners LLC, Janus Henderson Group PLC, Public Employees Retirement Association of Colorado, Teachers Advisors LLC and Strs Ohio. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein, Peter A Mcclennen and Stephany Verstraete. View Insider Buying and Selling for Teladoc Health.
Which institutional investors are buying Teladoc Health stock?
TDOC stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Capital International Investors, Macquarie Group Ltd., Artemis Investment Management LLP, Green Valley Investors LLC, Marshall Wace North America L.P., Neuberger Berman Group LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Teladoc Health.
How do I buy shares of Teladoc Health?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teladoc Health's stock price today?
One share of TDOC stock can currently be purchased for approximately $55.36.
How big of a company is Teladoc Health?
Teladoc Health has a market capitalization of $3.74 billion and generates $233.28 million in revenue each year. The health services provider earns $-106,780,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Teladoc Health employs 1,231 workers across the globe.
What is Teladoc Health's official website?
How can I contact Teladoc Health?
Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc Health (NYSE TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc Health and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
